Precision Targeting GTPases in Cancer, Autoimmunity and Fibrosis Precision Targeting GTPases in Cancer, Autoimmunity and Fibrosis MBQ-167 Our lead compound, MBQ-167, is a first-in-class therapeutic which simultaneously inhibits both Rac and CDC42, removing pre-existing metastases. MBQ-167 is currently in its Phase-1 study. Prevention of Metastatic Growth and